PureTech has initiated a clinical study to evaluate the safety and effectiveness of its experimental therapy LYT-100 in people with idiopathic pulmonary fibrosis (IPF). “We are excited to be taking this important step towards our goal of helping patients with this devastating condition,” Julie Krop, MD, PureTech’s chief…
PureTech Launches Phase 2 Trial of LYT-100 in IPF Patients
Algernon Pharmaceuticals has secured a patent in Canada covering the use of NP-120 (ifenprodil) as a treatment for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases driven by uncontrolled scarring in the lungs. The patent (No. 3101853), “Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis,” was issued by…
Living with a chronic illness is not for the faint of heart. In addition to the physical and emotional aspects of having a life-threatening lung disease like idiopathic pulmonary fibrosis (IPF), there are also many mental challenges. As patients, we’re often forced to face our fears, especially during acute…
Do you recall the first time you were allowed to stay home alone? Perhaps your parents had a date night. Maybe they had to work late. Whatever the reason, it was a sign you were considered responsible if you were trusted enough to be home alone. You knew that you…
The U.S. Food and Drug Administration (FDA) has given Daewoong Pharmaceutical the go-ahead to start a Phase 2 clinical trial to test the company’s experimental anti-fibrotic medication DWN12088 in people with idiopathic pulmonary fibrosis (IPF). “The existing treatments of Idiopathic pulmonary fibrosis still have high unmet medical needs.
Participants in a Phase 2 trial testing Algernon Pharmaceuticals’ NP-120 (ifenprodil) in people with chronic cough associated with idiopathic pulmonary fibrosis (IPF) have asked to have the experimental medication for their personal use, Algernon announced. The company noted in a press release that it’s “not making any express or…
“I’m so busy” feels like it’s now a common response to the question, “How are you?” It’s like being busy is glorified or worn as a badge of honor among many of us, myself included. Living with idiopathic pulmonary fibrosis (IPF), a life-threatening and debilitating lung disease, has forced…
Cymerus mesenchymal stem cells (MSCs), Cynata Therapeutics’ experimental cell therapy, significantly lowered the levels of pro-inflammatory and pro-scarring molecules in the lungs of a mouse model of idiopathic pulmonary fibrosis (IPF), the company announced. The “highly potent” therapy also was shown to significantly reduce immune cell infiltration, and the…
Prior to my diagnosis of idiopathic pulmonary fibrosis in 2017, my day started the same way almost every morning. I’d pick up my smartphone and see how the markets performed overnight. Then I’d look for an expected opening, based on the overseas markets. Since my diagnosis, I no longer…
Mesenchymal stem cells (MSCs) grown in three-dimension (3D) conditions produce tiny extracellular vesicles (EVs) that do not retain the anti-scarring and anti-inflammatory properties seen when they are derived from MSCs grown in two dimensions (2D), a study shows. These findings, obtained from treating a mouse model of pulmonary fibrosis…
